Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fresh Tracks Therapeutics, Inc.FRTX · Entity 90076 | Director · CEO and CFO | December 28, 2023 | January 09, 2024 |
| NexImmune, Inc.NEXI · Entity 89921 | See Remarks | April 05, 2024 | April 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fresh Tracks Therapeutics, Inc.
Report date December 28, 2023 · Filed January 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-28 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment"). F2: The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment").
F2: The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs.
NexImmune, Inc.
Report date April 05, 2024 · Filed April 10, 2024
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PDS Biotechnology Corp
Report date November 22, 2017 · Filed December 31, 2018 · Amendment
Section 16 reporting ended · disclosed 2018-12-31. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirect401(K) Plan | 11,349.13 |
Reported balance
Holding disclosure · report date 2017-11-22 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 11,349.13 F1: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2023 Filed Jan 9, 2024 16:10 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | Disposition to issuerRestricted Stock Units · Derivative | 1,250 | $0.91 | $1,137.50 |
DisclosureSEC source: 0001628280-24-000949 · wk-form4_1704834595.xml · derivative · entry 1 Marchio Albert N II · CIK 0001196054 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · derivative.exercise_price: Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment"). F1 · price: Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment"). F2 · derivative.exercise_date: The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs. F2 · derivative.expiration_date: The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 18:48 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | GrantRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000819050-23-000006 · wf-form4_167477690143545.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of issuer common stock upon settlement. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Read SEC document |
| May 05, 2022 Filed May 9, 2022 16:16 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000819050-22-000046 · wf-form4_165212737833226.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-05 F1 · derivative.exercise_date: The stock options will vest 25% on the first anniversary of the grant date, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 16:46 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000819050-21-000090 · wf-form4_162370354842269.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The stock options will vest 25% on June 14, 2022, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 11:59 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 41,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025370 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 41,666 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:39 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 83,334 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021594 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,334 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 13:22 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 25,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001127602-18-009808 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 25,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 23:50 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 50,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-18-000817 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-02 Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 20:08 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 3,361 | $10.00 | $33,610.00 |
DisclosureSEC source: 0001127602-17-033177 · form4.xml · nonDerivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 29, 2017 Filed Aug 29, 2017 21:30 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 2,500 | $10.42 | $26,050.00 |
DisclosureSEC source: 0001127602-17-026651 · form4.xml · nonDerivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361 F1 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.47 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 20:11 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 1,000 | $10.39 | $10,390.00 |
DisclosureSEC source: 0001127602-17-026402 · form4.xml · nonDerivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Adm Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,861 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 19:32 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (right To Purchase) · Derivative | 47,500 | $8.86 Strike: $8.86 | $420,850.00 |
DisclosureSEC source: 0001127602-17-011767 · form4.xml · derivative · entry 1 MARCHIO ALBERT N II · CIK 0001196054 · Chief Accounting & Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2027-03-13 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 47,500 shares of Common Stock, will become exercisable on February 17, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.